Responsibility Statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements of the Merck Group give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group for the remaining months of the financial year.

Darmstadt, May 13, 2013

Karl-Ludwig Kley | Kai Beckmann | Stefan Oschmann

Bernd Reckmann | Matthias Zachert

Interim Consolidated Financial Statements as of March 31, 2013

Consolidated Income Statement

€ million	Q1 – 2013	Q1 – 2012
Sales	**2,660.4**	**2,563.9**
Royalty, license and commission income	100.1	81.1
Total revenues	**2,760.5**	**2,644.9**
Cost of sales	–724.0	–748.7
Gross profit	**2,036.5**	**1,896.2**
Marketing and selling expenses	–568.3	–586.6
Royalty, license and commission expenses	–136.3	–120.0
Administration expenses	–132.7	–136.4[1]
Other operating expenses and income	–184.0	–144.6
Research and development	–406.2	–381.8
Amortization of intangible assets	–209.6	–216.3
Investment result	–	–
Operating result (EBIT)	**399.4**	**310.6**[1]
Financial result	–58.7	–66.1[1]
Profit before income tax	**340.7**	**244.5**[1]
Income tax	–71.7	–69.4
Profit after tax	**269.0**	**175.1**[1]
of which attributable to Merck KGaA shareholders (net income)	266.0	172.7[1]
of which attributable to non-controlling interest	3.0	2.4
Earnings per share (in €)		
basic	1.22	0.79[1]
diluted	1.22	0.79[1]

[1] Previous year's figures have been adjusted, see explanation on page 27

Consolidated Statement of Comprehensive Income

€ million	Q1 – 2013	Q1 – 2012
Profit after tax	**269.0**	**175.1**[1]
Items of other comprehensive income that will not be reclassified to the income statement in subsequent periods:		
Remeasurement of the net defined benefit liability		
Changes in remeasurement	–87.8	–[1]
Deferred taxes	14.7	–
Changes recognized in equity	**–73.1**	**–**[1]
	–73.1	**–**
Items of other comprehensive income that may be reclassified to the income statement in subsequent periods:		
Available-for-sale financial assets		
Fair value adjustments	0.7	–
Reclassification to income statement	–	–
Deferred taxes	–0.4	–
Changes recognized in equity	**0.3**	**–**
Derivative financial instruments		
Fair value adjustments	–21.4	25.6
Reclassification to income statement	–3.1	42.0
Deferred taxes	7.5	–10.1
Changes recognized in equity	**–17.0**	**57.5**
Exchange differences on translating foreign operations		
Changes taken directly to equity	21.0	–19.4
Reclassification to income statement	–	–
Changes recognized in equity	**21.0**	**–19.4**
	4.3	**38.1**
Other comprehensive income	**–68.8**	**38.1**[1]
Comprehensive income	**200.2**	**213.2**[1]
of which attributable to Merck KGaA shareholders	195.4	210.9[1]
of which attributable to non-controlling interest	4.8	2.3

[1] Previous year's figures have been adjusted, see explanation on page 27

Consolidated Balance Sheet

€ million	March 31, 2013	December 31, 2012
Current assets		
Cash and cash equivalents	814.0	729.7
Current financial assets	2,087.3	1,797.9
Trade accounts receivable	2,254.8	2,114.6
Inventories	1,559.4	1,533.9
Other current assets	319.8	271.5
Income tax receivables	81.8	178.5
	7,117.0	**6,626.1**
Non-current assets		
Intangible assets	10,825.4	10,944.5
Property, plant and equipment	2,863.6	2,953.6
Non-current financial assets	67.5	97.1
Other non-current assets	69.2	75.4
Deferred tax assets	1,011.2	946.6
	14,836.8	**15,017.2**
Total assets	**21,953.8**	**21,643.3**
Current liabilities		
Current financial liabilities	1,103.1	1,091.4
Trade accounts payable	1,252.3	1,288.3
Other current liabilities	1,173.9	1,096.2
Income tax liabilities	448.3	401.4
Current provisions	642.9	684.3
	4,620.5	**4,561.6**
Non-current liabilities		
Non-current financial liabilities	3,365.3	3,362.1
Other non-current liabilities	16.6	9.4
Non-current provisions	947.1	891.7
Provisions for pensions and other post-employment benefits	1,308.3	1,211.7
Deferred tax liabilities	1,181.7	1,192.0
	6,818.9	**6,666.9**
Equity		
Equity capital	565.2	565.2
Reserves	8,648.7	8,552.3
Gains/losses recognized immediately in equity	1,246.4	1,243.9
Equity attributable to Merck KGaA shareholders	**10,460.3**	**10,361.4**
Non-controlling interest	54.0	53.4
	10,514.3	**10,414.8**
Total liabilities and equity	**21,953.8**	**21,643.3**

Consolidated Cash Flow Statement

€ million	Q1 – 2013	Q1 – 2012
Profit after tax	**269.0**	**175.1**[1]
Depreciation/amortization/impairment losses/write-ups	354.4	342.7
Changes in inventories	–21.0	7.0
Changes in trade accounts receivable	–134.2	–44.2
Changes in trade accounts payable	–39.5	26.1
Changes in provisions	22.7	24.4[1]
Changes in other assets and liabilities	71.9	–52.3[1]
Neutralization of gain/loss on disposals of assets	–4.4	–10.1
Other non-cash income and expenses	–3.1	3.2
Net cash flows from operating activities	**515.7**	**471.9**
Investments in intangible assets	–28.9	–29.1
Investments in property, plant and equipment	–37.5	–50.7
Acquisitions	–	–
Investments in non-current financial assets	–19.4	–5.6
Disposal of non-current assets	8.7	31.4
Purchase/sale of marketable securities	–	1.7
Changes in other financial assets	–247.2	370.2
Net cash flows from investing activities	**–324.3**	**318.0**
Dividend payments	–1.9	–0.7
Profit transfers to E. Merck KG and changes in reserves	–98.7	–69.0
Changes in liabilities to E. Merck KG	52.5	–10.0
Repayment of bonds	–	–500.0
Changes in current and non-current financial liabilities	–58.6	–58.2
Net cash flows from financing activities	**–106.7**	**–637.9**
Changes in cash and cash equivalents	**84.7**	**152.0**
Changes in cash and cash equivalents due to currency translation	–0.4	–3.0
Cash and cash equivalents as of January 1	729.7	937.8
Cash and cash equivalents as of March 31	**814.0**	**1,086.8**

[1] Previous year's figures have been adjusted, see explanation on page 27

Consolidated Statement of Changes in Equity

€ million	Equity capital: General partner's equity Merck KGaA	Equity capital: Subscribed capital Merck KGaA	Capital reserves (share premium) Merck KGaA	Retained earnings: Retained earnings/Net retained profit	Retained earnings: Remeasurement of defined benefit plans	Gains/losses recognized immediately in equity: Available-for-sale financial assets	Gains/losses recognized immediately in equity: Derivative financial instruments	Gains/losses recognized immediately in equity: Currency translation difference	Equity attributable to Merck KGaA shareholders	Non-controlling interest	Equity
Balance as of January 1, 2012[1]	**397.2**	**168.0**	**3,813.7**	**5,237.1**	**–378.2**	**0.8**	**–94.6**	**1,304.0**	**10,448.0**	**46.3**	**10,494.3**
Profit after tax[1]	–	–	–	172.7	–	–	–	–	172.7	2.4	175.1
Other comprehensive income[1]	–	–	–	–	–	–	57.5	–19.2	38.3	–0.2	38.1
Comprehensive income[1]	**–**	**–**	**–**	**172.7**	**–**	**–**	**57.5**	**–19.2**	**210.9**	**2.3**	**213.2**
Dividend payments	–	–	–	–	–	–	–	–	–	–0.7	–0.7
Profit transfers to/from E. Merck KG including changes in reserves	–	–	–	–69.0	–	–	–	–	–69.0	–	–69.0
Changes in scope of consolidation/Other	–	–	–	0.6	–	–	–	–	0.6	–0.2	0.4
Balance as of March 31, 2012[1]	**397.2**	**168.0**	**3,813.7**	**5,341.4**	**–378.2**	**0.8**	**–37.1**	**1,284.8**	**10,590.6**	**47.6**	**10,638.2**
Balance as of January 1, 2013	**397.2**	**168.0**	**3,813.7**	**5,383.9**	**–645.3**	**1.2**	**–29.5**	**1,272.2**	**10,361.4**	**53.4**	**10,414.8**
Profit after tax	–	–	–	266.0	–	–	–	–	266.0	3.0	269.0
Other comprehensive income	–	–	–	–	–73.1	0.3	–17.0	19.2	–70.6	1.8	–68.8
Comprehensive income	**–**	**–**	**–**	**266.0**	**–73.1**	**0.3**	**–17.0**	**19.2**	**195.4**	**4.8**	**200.2**
Dividend payments	–	–	–	–	–	–	–	–	–	–1.9	–1.9
Profit transfers to/from E. Merck KG including changes in reserves	–	–	–	–98.7	–	–	–	–	–98.7	–	–98.7
Transactions with no change of control	–	–	–	2.1	–	–	–	–	2.1	–2.1	–
Changes in scope of consolidation/Other	–	–	–	0.2	–	–	–	–	0.2	–0.2	–
Balance as of March 31, 2013	**397.2**	**168.0**	**3,813.7**	**5,553.4**	**–718.4**	**1.5**	**–46.5**	**1,291.4**	**10,460.3**	**54.0**	**10,514.3**

[1] Previous year's figures have been adjusted, see explanation on page 27